Department of Anesthesiology, Weifang People's Hospital, Weifang, Shandong, China.
Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2561-2566.
To explore the relationship between IgH gene rearrangement and orbital MALT (mucose-associated lymphoid tissue) lymphoma removal operation prognosis, and to quantify the effect of IgH gene rearrangement on primary orbital MALT lymphoma prognosis.
Fifty-eight patient cases with primary orbital MALT lymphoma were included in this study. Orbital lymphoma specimens were embedded in paraffin for sectioning. IgH gene rearrangement was detected using PCR. The correlation between IgH gene rearrangement and the patient recurrence and survival rates were determined using statistical analysis. The aforementioned rates were calculated and a survival curve was determined. p-values lower than 0.05 was considered statistically significant.
We found that the 5-year disease-free survival rate was 90.8% in patients with orbital MALT lymphoma (mean value 56.7 months, range 52-60 months). The use of IgH gene rearrangement detection methods found that the non-recurrence rate of primary orbital MALT lymphoma cases was 79.3%. Survival analysis revealed that IgH gene rearrangement was significantly correlated with recurrence of orbital MALT lymphoma (p<0.001).
IgH gene rearrangement detection can be improved by the combined usage of multiple primer pairs, especially family specific primers. In the future, detection of IgH gene rearrangement may be used as a novel marker to predict the prognosis of patients with primary orbital MALT lymphoma.
探讨 IgH 基因重排与眼眶黏膜相关淋巴组织（mucose-associated lymphoid tissue，MALT）淋巴瘤切除手术预后的关系，并定量分析 IgH 基因重排对原发性眼眶 MALT 淋巴瘤预后的影响。
纳入 58 例原发性眼眶 MALT 淋巴瘤患者。将眼眶淋巴瘤标本包埋在石蜡中进行切片。采用 PCR 检测 IgH 基因重排。采用统计学分析确定 IgH 基因重排与患者复发率和生存率的相关性。计算上述比率并绘制生存曲线。p 值小于 0.05 被认为具有统计学意义。
我们发现，眼眶 MALT 淋巴瘤患者的 5 年无病生存率为 90.8%（平均值为 56.7 个月，范围为 52-60 个月）。使用 IgH 基因重排检测方法发现，原发性眼眶 MALT 淋巴瘤病例的无复发率为 79.3%。生存分析表明，IgH 基因重排与眼眶 MALT 淋巴瘤的复发显著相关（p<0.001）。
通过联合使用多对引物，特别是家族特异性引物，可以提高 IgH 基因重排的检测。将来，检测 IgH 基因重排可能被用作预测原发性眼眶 MALT 淋巴瘤患者预后的新标志物。
